Research programme: MOR 101 antibodies - MorphoSys

Drug Profile

Research programme: MOR 101 antibodies - MorphoSys

Alternative Names: MOR 101 antibodies (Fab fragment); MOR 101 antibodies research programme - MorphoSys; MOR101

Latest Information Update: 16 Mar 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MorphoSys
  • Class
  • Mechanism of Action Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Burns

Most Recent Events

  • 24 Feb 2006 Discontinued - Preclinical for Burns in Germany (unspecified route)
  • 16 May 2005 This programme is still in active development - (BioSquare-2005)
  • 27 Jun 2003 MOR 101 is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top